NEWS & VIEWS
The only genes with any reasonable homology to mammalian LGI1 are the Drosophila slit and toll genes, which are expressed in the midline glial cells. At this time, the Drosophila genes provide the only real clue to the potential function of LGI1. As axons migrate through the developing nervous system, they integrate, and respond to, a variety of adhesive, attractive and repellant signals that are received as a result of cell-cell contact or from diffusion through the extracellular matrix 8 . As brain-tumor cells spread, they too must navigate through brain tissue and process the various signals of cell and matrix origin that they encounter. In Drosophila, the slit pathway sends a repellant signal from midline glial cells to prevent axon crossing, and ultimately controls cell positioning 9 . Does LGI1 perform a similar function in human brain and does absence of LGI1 expression enable tumor cells to ignore normal signals that would regulate their ability to pass through brain tissue? It is an intriguing thought, as LGI1 function is lost in many tumors that infiltrate the brain.
Analysis of another tumor suppressor gene, PTEN, has recently provided evidence for a link between neural stem cells and brain tumors. Pten is mutated in a variety of tumors and, like LGI1, appears to be involved in the late stages of brain-tumor development 10 . Groszer et al. 11 showed that Pten is a negative regulator of neural stem-cell proliferation. Mice carrying conditional mutations in Pten have seizures and ataxia due to a disturbed patterning of cells in the brain. This altered cell-fate commitment of neural stem cells was suggested to be due to abnormalities in cell adhesion and migration. The PTEN story thus appears to be similar to the one proposed above for the role of LGI1 in epilepsy and brain tumors. It should be kept in mind that the only homology LGI1 has with Drosophila slit is in the LRR domain. Even if the function of this motif is the same in humans and flies, the downstream consequences of cell and matrix interactions could be very different. slit also has a role in axon guidance in other sensory systems that may be relevant to the auditory abnormalities in the ADPEAF.
The demonstration that epilepsy may be caused by abnormal crosstalk in the complex network of cells in the brain adds a new dimension to this disease beyond deregulation of ion balance in neurons. Regardless of what the eventual function of LGI1 is shown to be, the truly exciting opportunity is that future research will combine the elegant techniques of the developmental neurobiologists with the extensive ability of cancer-cell biologists to manipulate gene function in tumor cells. This combination should accelerate our un- T he ultimate goal in clinical transplantation is to induce a state of donor-specific immunologic tolerance, where recipients can accept organs, tissues or cell grafts without the need of exogenous immunosuppression 1 . But to achieve this goal, we must first understand the exact cellular and molecular mechanisms of both acute and chronic graft rejection. In this issue, Kreisel et al. 2 highlight a potentially critical role of CD8 + T cell-endothelial cell interactions in mediating graft rejection. The study raises the important question: Where do T cells meet transplant antigens in the context of planning and initiating the alloimmune response that ultimately results in graft destruction?
Transplantation is the treatment of choice for end-stage failure of organs such as kidney, heart, lung, liver and pancreas. In the absence of exogenous immunosuppressive drugs, transplanted organs are almost invariably rejected. Even with potent immunosuppressive drugs, a significant proportion of transplanted organs undergo acute rejection (although the number has been declining with use of newer immunosuppressive strategies). However, the main problem in clinical transplantation, aside from organ shortage, has been the occurrence of slow, progressive organ dysfunction resulting in chronic attrition of grafts over time-a process often referred to as chronic rejection 3 . T cells are essential for both acute and chronic graft rejection 3, 4 . The first step in an alloimmune response is a 'rendezvous' between T cells and transplant antigens where allorecognition occurs. There are two distinct though not necessarily mutually exclusive pathways of allorecognition 3 ( Fig. 1a) . First, T cells can recognize intact major histocompatibil-
derstanding of the role of LGI1 in the basic biology of both diseases. sional hematopoietic antigen-presenting cells. On the surface, the latter finding appears to challenge the observations of Lakkis et al. 12 . They showed that peripheral lymphoid organs are required for allograft rejection, which implies that unprimed T cells must encounter antigens first outside the graft, in the guise of donor antigenpresenting cells that have migrated to host lymph nodes or processed allopeptides presented by self-antigen presenting cells. However, it is also possible that T cells, after recognizing antigens on graft endothelium, migrate to peripheral lymphoid organs for further maturation and differentiation before they are recruited back to the graft to effect tissue destruction.
Thus, taking the current study and earlier findings together, one can envision that graft endothelial cells that are present for the lifetime of the organ can be important players in promoting both direct and indirect allorecognition leading to acute and/or chronic rejection (Fig. 1b) .
The unique property of graft endothelial cells to promote direct allorecognition may be critical for activation of alloreactive CD8 + T cells, especially in situations where CD4 + T-cell activation has been inhibited, such as with T-cell costimulatory blockade 13 . What is unknown, however, is whether endothelial cells in vivo function to present antigen and activate CD8 + T cells that in turn kill graft cells, whether they merely serve as targets for CD8 + T cell-mediated cytotoxicity, or both.
Several other questions remain to be answered. First, what is the physiologic relevance of the reported observations in normal non-transgenic animals and ultimately humans? Second, are there unique T-cell costimulatory pathways that provide second signals to T cells activated by endothelial cells 14 ? Third, what is the relative contribution of this unique allorecognition mechanism to acute and chronic rejection? Fourth, how can these data be reconciled with the observations of Lechler's group suggesting that activated endothelial cells can in fact tolerize T cells activated via the direct pathway of allorecognition 15, 16 ? And are these differences related to the tissue source of endothelial cells? Finally, what is the role of this unique allorecognition mechanism in resistance to tolerance? These clinically relevant questions require further investigation. ity complex molecules on donor cells; this is, the 'direct' allorecognition pathway. T cells can also recognize processed alloantigens in the form of peptides presented by the recipient's antigen-presenting cells. This 'indirect' pathway of allorecognition is analogous to that of physiologic antigen recognition. Indirect allorecognition has been shown to have a role in acute rejection 5 , but it also has been postulated to play a crucial part in the development and progression of chronic allograft rejection 6 . Endothelial cells of donor origin are uniquely located at the interface between the recipient's blood and the allograft, and they have been implicated in graft rejection 7 .
Endothelial cells may promote indirect allorecognition by a crosstalk mechanism, which involves the recruitment and transformation of recipient monocytes by endothelial cells into highly efficient antigenpresenting dendritic cells 8, 9 . These dendritic cells may recirculate to peripheral lymphoid organs for maturation and, in turn, present alloantigen via the indirect pathway to memory T cells in the periphery or in the transplanted tissue (Fig. 1b) .
Graft endothelial cells also express major histocompatibility complex class I and II molecules and have been long suspected to directly stimulate T cells, although in vivo evidence was lacking until now. Graft endothelial cells can induce proliferation of, and cytokine production by, allogeneic T cells in vitro 10 , and induce and regulate cytolytic T-cell differentiation 11 . The data suggest that graft endothelial cells could promote direct allorecognition by either serving as antigen-presenting cells and/or as targets for T cell-mediated cytotoxicity.
To address this question, Kreisel et al. used an elegant transgenic animal model system to make two important and novel observations. 
The hope is that the results of these investigations will give rise to the development of novel and reproducible strategies to induce donor-specific immunologic tolerance that can be translated effectively from rodent models to primates and ultimately humans 1 .
Shrinking genes for therapy
Gene therapy holds great promise for treating many genetic diseases. But what happens if the gene to be 'fixed' is just too big to be delivered to the affected tissue? Researchers have tried to get over the obstacle by creating reduced versions of large genes, such as the 2.4-megabase dystrophin gene that is mutated in patients with Duchenne muscular dystrophy (DMD). A study in this issue uses micro-dystrophin constructs to correct the DMD phenotype in a mouse model of the disease, suggesting that gene therapy of DMD might be feasible.
There is currently no treatment for DMD, a lethal X-linked disease caused by mutations that eliminate production of the muscle protein dystrophin or result in truncated, nonfunctional versions of the protein.
Muscles lacking functional dystrophin (in particular, skeletal limb, cardiac and diaphragm muscles) are susceptible to mechanical damage and progressively degenerate. The dystrophin-deficient mdx mouse provides an animal model to study DMD.
Based on previous structure-function analyses of different portions of dystrophin in transgenic mdx mice, Jeffrey Chamberlain, Scott Harper and colleagues at the University of Washington School of Medicine generated extremely small dystrophins with similar function to that of the full-length protein. The authors then tested their micro-dystrophin constructs in both transgenic and viral-mediated gene-transfer models to see whether they could prevent and reverse the disease phenotype, respectively.
Transgenic mdx mice expressing different micro-dystrophins were protected against damage caused by muscle activity and appeared morphologically identical to normal mice. But the morphologically rescued muscles were weaker than controls. Based on these results, the authors speculate that gene therapy using micro-dystrophins might be effective in preventing ongoing muscle damage, but may not be sufficient to fully restore muscle strength. Interestingly, several of the constructs tested were more effective in preventing dystrophy in diaphragm than limb muscles. The results are relevant to the development of gene therapy of DMD as the diaphragm is the most severely affected muscle in DMD patients, who typically die of respiratory failure.
Another encouraging finding was that viral injection of the dystrophin constructs into dystrophic muscles of immunocompetent mice produced a dramatic reversal of some of the disease-associated changes in muscle fiber morphology. The photograph shows a section of mdx muscle injected with AAV2 micro-dystrophin virus stained by immunofluorescence. Micro-dystrophin, which localizes to the cell membrane, is labeled green and nuclei are labeled blue (DAPI stain). The red staining represents Evans blue dye (EBD) and indicates muscle-membrane permeability, a characteristic feature of dystrophic fibers. In their study (reported on pages 253-261), Harper et al. found a decrease in EBD staining in muscles injected with the micro-dystrophin constructs compared with untreated muscle. More importantly, the injected muscles displayed far fewer centrally nucleated fibers, and had significantly more uniform fiber diameters than uninjected muscles.
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